Utah Medical Products (UTMD) AI Stock Analysis

• Market Cap: $181.44M
• Dividend Yield: 2.14%
• Average Volume (3M): 7.74K
• Price to Earnings (P/E): 16.1
• Beta (1Y): 0.53
• Revenue Growth: -12.35%
• EPS Growth: N/A
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.82
• Shares Outstanding: 3,205,723
• 10 Day Avg. Volume: 6,645
• 30 Day Avg. Volume: 7,742
• PEG Ratio: -1.16
• Price to Book (P/B): 1.83
• Price to Sales (P/S): 5.26
• P/FCF Ratio: 14.75
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 3.04
• Enterprise Value/Gross Profit: 5.43
• Enterprise Value/Ebitda: 7.46
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: $63.00 ▲(3.67% Upside)

Utah Medical Products' strong financial performance is the most significant factor, supported by solid profitability and a robust balance sheet. However, technical analysis indicates bearish momentum, which weighs down the overall score. The valuation is neutral, providing neither a strong positive nor negative impact.

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a medical device company that specializes in the development, manufacture, and marketing of proprietary medical products primarily for use in the hospital and home healthcare settings. The company operates in several sectors, including obstetrics, urology, and surgery, and offers a range of core products such as disposable surgical devices, urodynamic equipment, and neonatal care products designed to improve patient outcomes and enhance healthcare efficiency.

How the Company Makes Money

UTMD generates revenue primarily through the sale of its medical devices, which are distributed to hospitals, clinics, and healthcare providers both domestically and internationally. The company's revenue model is based on the direct sales of its proprietary products, which are often sold under long-term contracts or as part of bulk orders. Key revenue streams include sales from its obstetric and urological product lines, as well as ongoing revenue from consumables and accessories related to these devices. Additionally, UTMD benefits from strategic partnerships with medical distributors and healthcare organizations, which enhance its market reach and contribute to consistent sales growth. The company also invests in research and development to innovate and expand its product offerings, thereby driving future revenue potential.

Utah Medical Products Financial Statement Overview

Summary

Utah Medical Products demonstrates strong financial health with solid profitability, a robust balance sheet, and strong cash flow generation. Despite a decline in revenue growth, the company's efficient operations and low leverage position it well for future stability and potential growth.

Income Statement

Utah Medical Products shows strong profitability with a consistent net profit margin above 30% and a solid EBIT margin. However, the company has experienced a decline in revenue growth, with a negative growth rate in the TTM period. Despite this, the gross profit margin remains healthy, indicating efficient cost management.

Balance Sheet

The balance sheet is robust with a very low debt-to-equity ratio, indicating minimal leverage and financial risk. The return on equity is stable, reflecting efficient use of equity to generate profits. The equity ratio is strong, suggesting a solid capital structure with a high proportion of equity financing.

Cash Flow

Cash flow metrics are strong, with a high operating cash flow to net income ratio, indicating good cash generation relative to earnings. Free cash flow growth has been positive in the TTM period, although it has fluctuated in previous years. The free cash flow to net income ratio is close to 1, showing effective cash conversion from profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.83M	40.90M	50.22M	52.28M	49.05M	42.18M
Gross Profit	21.72M	24.14M	30.04M	32.20M	30.92M	25.55M
EBITDA	15.80M	16.44M	24.75M	26.87M	26.16M	20.92M
Net Income	12.55M	13.87M	16.64M	16.47M	14.79M	10.80M
Balance Sheet
Total Assets	120.80M	122.54M	135.46M	123.87M	115.56M	111.75M
Cash, Cash Equivalents and Short-Term Investments	82.18M	82.98M	92.87M	75.05M	60.97M	51.59M
Total Debt	256.00K	338.00K	295.00K	341.00K	396.00K	335.00K
Total Liabilities	3.27M	5.11M	7.14M	9.62M	8.50M	8.92M
Stockholders Equity	117.53M	117.43M	128.31M	114.25M	107.14M	102.82M
Cash Flow
Free Cash Flow	14.02M	14.60M	21.64M	20.33M	20.65M	19.28M
Operating Cash Flow	14.13M	14.83M	22.28M	21.15M	21.20M	20.14M
Investing Cash Flow	-333.00K	-208.00K	-639.00K	-818.00K	-552.00K	-860.00K
Financing Cash Flow	-21.39M	-23.84M	-4.17M	-5.48M	-10.90M	-10.73M

Utah Medical Products Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 60.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Negative. The current price of 60.77 is below the 20-day moving average (MA) of 60.97, below the 50-day MA of 61.46, and above the 200-day MA of 57.57, indicating a bearish trend. The MACD of -0.84 indicates Positive momentum. The RSI at 29.78 is Positive, neither overbought nor oversold. The STOCH value of 7.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UTMD.

Utah Medical Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	―	$204.26M	42.16	9.39%	―	8.13%	1293.06%
UTMD	―	$181.44M	16.13	9.59%	2.14%	-12.35%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	―	$262.09M	―	-25.78%	―	34.29%	-49.21%
KRMD	―	$182.63M	―	-25.63%	―	19.57%	61.81%
POAI	―	$35.63M	-0.40	-708.73%	―	-38.79%	58.27%

Utah Medical Products Corporate Events

Utah Medical Products Faces Trade Challenges in 2025

Utah Medical Products, Inc., a company specializing in healthcare devices for women and infants, develops, manufactures, and markets a wide range of medical devices recognized globally for their quality and effectiveness. In its latest earnings report, Utah Medical Products faced challenges due to global trade uncertainties, resulting in a decline in financial performance for the third quarter and first nine months of 2025 compared to the previous year. The company’s revenue, gross profit, and net income all saw declines, with revenues dropping by 2% for the quarter and 7% for the nine months. The company attributed these declines to the cancellation or delay of orders by international distributors and increased operating expenses. Despite these setbacks, Utah Medical Products maintained a strong balance sheet with no debt and continued to repurchase shares, reflecting confidence in its long-term prospects. Looking ahead, the company anticipates a challenging environment but remains committed to maintaining its financial health and operational efficiency.